Purchases through the above links give commission which helps fund this website
Recent literature: Phosphodiesterase-4 inhibitor
Date Journal Article title
2019 Oct Cell Mol Neurobiol Inhibition of PDE4 Attenuates TNF-α-Triggered Cell Death Through Suppressing NF-κB and JNK Activation in HT-22 Neuronal Cells.
2019 Oct J Dermatol Phase 1 study of crisaborole in Japanese healthy volunteers and patients with atopic dermatitis.
2012 LiverTox: Clinical and Re... Roflumilast
2012 LiverTox: Clinical and Re... Apremilast
2019 Oct Redox Biol Inhibition of PDE4 protects neurons against oxygen-glucose deprivation-induced endoplasmic reticulum stress through activation of the Nrf-2HO-1 pathway.
2019 Aug Eur J Dermatol Efficacy of the phosphodiesterase-4 inhibitor, apremilast, in a patient with severe alopecia areata.
2019 Pharmacol Res Biological and synthetic target DMARDs in psoriatic arthritis.
2019 Oct J Aerosol Med Pulm Drug D... Detrimental Effects of an Inhaled Phosphodiesterase-4 Inhibitor on Lung Inflammation in Ventilated Preterm Lambs Exposed to Chorioamnionitis Are Dose Dependent.
2019 Sep Drug Discov Today Soft drugs for dermatological applications: recent trends.
2019 Expert Opin Investig Drugs Ensifentrine (RPL554): an investigational PDE34 inhibitor for the treatment of COPD.
2019 J Allergy Clin Immunol Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial.
2019 Aug J Am Acad Dermatol Pharmacokinetics and Safety of Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: Results From a Phase 2 Open-Label Study.
2019 Aug Respir Res Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD.
2019 Jul Cell Death Dis Shifting the balance of autophagy and proteasome activation reduces proteotoxic cell death: a novel therapeutic approach for restoring photoreceptor homeostasis.
2019 Immunol Med Novel topical and systemic therapies in atopic dermatitis.
2019 Brain Behav Fear renewal activates cyclic adenosine monophosphate signaling in the dentate gyrus.
2019 Jul J Am Acad Dermatol Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: a double-blind, randomized, vehicle-controlled trial.
2019 Am J Clin Dermatol Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups.
2019 Jun Br J Dermatol Apremilast in chronic recalcitrant erythema nodosum leprosum: a report of two cases.
2019 Diabetes Metab Syndr Obes Early effects of roflumilast on insulin sensitivity in adults with prediabetes and overweightobesity involve age-associated fat mass loss - results of an exploratory study.
2019 Jun Rheumatology (Oxford) Apremilast increases IL-10-producing regulatory B cells and decreases proinflammatory T cells and innate cells in psoriatic arthritis and psoriasis.
2019 Therap Adv Gastroenterol New biologics and small molecules in inflammatory bowel disease: an update.
2019 Biologics Outcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of Hallopeau.
2019 J Dermatol Drug survival of apremilast in a real-world setting.
2018 Best Pract Res Clin Rheum... Emerging treatment options for spondyloarthritis.
2019 Environ Toxicol Pivotal role of cAMP-PKA-CREB signaling pathway in manganese-induced neurotoxicity in PC12 cells.
2019 Indian J Dermatol Apremilast Coadministered with Secukinumab for Safe and Effective Control of Psoriasis with Resultant Reduction of Maintenance Dose of the Biologic.
2019 J Eur Acad Dermatol Venereol Examining the association between pruritus and quality of life in patients with atopic dermatitis treated with crisaborole.
2019 J Clin Aesthet Dermatol Recommendations for Initiating Systemic Therapy in Patients with Psoriasis.
2019 Jun J Med Chem Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines as Novel PDE4 Inhibitors Leading to Discovery of an Effective Antipsoriasis Agent.
2019 May Hepatology Phosphodiesterase 4 Inhibition as a Therapeutic Target for Alcoholic Liver Disease: From Bedside to Bench.
2019 J Comp Eff Res Treatment patterns and costs among biologic-naive patients initiating apremilast or biologics for psoriatic arthritis.
2019 CPT Pharmacometrics Syst ... Concentration-QT Modeling Following Inhalation of the Novel Inhaled Phosphodiesterase-4 Inhibitor CHF6001 in Healthy Volunteers Shows an Absence of QT Prolongation.
2019 Mol Pharmacol Impact of Phosphodiesterase 4 Inhibition on the Operational Efficacy, Response Maxima, and Kinetics of Indacaterol-Induced Gene Expression Changes in BEAS-2B Airway Epithelial Cells: A Global Transcriptomic Analysis.
2019 Jul Neuropharmacology The antidepressant- and anxiolytic-like effects of resveratrol: Involvement of phosphodiesterase-4D inhibition.
2019 Dermatol Ther Nails as immune-privileged sites: A case of disabling Acrodermatitis continua of Hallopeau successfully treated with Apremilast.
2019 J Dermatol Sci Cytochemokine profile of in vitro scratched keratinocyte model: Implications of significant upregulation of CCL20, CXCL8 and IL36G in Koebner phenomenon.
2019 J Surg Res Phosphodiesterase-4 Inhibitor Roflumilast Attenuates Pulmonary Air Emboli-Induced Lung Injury.
2019 Expert Opin Pharmacother Evaluating crisaborole as a treatment option for atopic dermatitis.
2019 Exp Ther Med Phosphodiesterase 4 inhibitor plus metformin is erior to metformin alone for the treatment of polycystic ovary syndrome: A rat model study.
2019 Skin Therapy Lett Crisaborole 2% Ointment (Eucrisa) for Atopic Dermatitis
2019 J Dermatol Favorable response to apremilast in a patient with refractory psoriasis verrucosa.
2019 Hautarzt [Gastrointestinal side effects of apremilast : Characterization and management].
2019 Apr J Dermatolog Treat Off-label studies on apremilast in dermatology: a review.
2019 Jul Acta Derm Venereol Direct and Indirect Effects of Crisaborole Ointment on Quality of Life in Patients with Atopic Dermatitis: A Mediation Analysis.
2019 Apr Life Sci Phosphodiestrase-1 and 4 inhibitors ameliorate liver fibrosis in rats: Modulation of cAMPCREBTLR4 inflammatory and fibrogenic pathways.
2019 Biochem Pharmacol The PDE4 inhibitor CHF6001 modulates pro-inflammatory cytokines, chemokines and Th1- and Th17-polarizing cytokines in human dendritic cells.
2019 Curr Top Med Chem Resveratrol in Various Pockets: A Review.
2019 Ther Adv Musculoskelet Dis IL-12IL-23p40 identified as a downstream target of apremilast in iex vivoi models of arthritis.
2019 Mar Neurosci Res Adolescent psychosocial stress enhances sensitization to cocaine exposure in genetically vulnerable mice.
2019 Apr Eur J Med Chem Discovery of arylbenzylamines as PDE4 inhibitors with potential neuroprotective effect.
2019 May Free Radic Biol Med Inhibition of PDE4 by FCPR16 induces AMPK-dependent autophagy and confers neuroprotection in SH-SY5Y cells and neurons exposed to MPP+-induced oxidative insult.
2019 Feb J Drugs Dermatol Apremilast for the Treatment of Mild-to-Moderate Hidradenitis Suppurativa in a Prospective, Open-Label, Phase 2 Study
2019 Biochem Pharmacol FCPR03, a novel phosphodiesterase 4 inhibitor, alleviates cerebral ischemiareperfusion injury through activation of the AKTGSK3β β-catenin signaling pathway.
2019 Neurobiol Aging Acute treatment with the PDE4 inhibitor roflumilast improves verbal word memory in healthy old individuals: a double-blind placebo-controlled study.
2019 Indian Dermatol Online J Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule.
2019 Apr Am J Physiol Lung Cell Mo... Extracellular vesicles: another compartment for the second messenger, cyclic adenosine monophosphate.
2019 Hum Exp Toxicol Roflumilast, a phosphodiesterase 4 inhibitor, attenuates cadmium-induced renal toxicity via modulation of NF-κB activation and induction of NQO1 in rats.
2019 Apr Eur J Pharmacol TAS-203, an oral phosphodiesterase 4 inhibitor, exerts anti-inflammatory activities in a rat airway inflammation model.
2019 Jan BMJ Case Rep Complete resolution of erythrodermic psoriasis with first-line apremilast monotherapy.
2019 Dermatol Ther (Heidelb) Tolerability of Topical Treatments for Atopic Dermatitis.
2018 Pharm Pat Anal Ensifentrine (RPL554): an inhaled 'bifunctional' dual PDE34 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease.
2019 J Med Econ Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
2019 Mol Med Rep Anti‑inflammatory effect of ciclamilast in an allergic model involving the expression of PDE4B.
2019 Ann Rheum Dis Association of synovial tissue polyfunctional T-cells with DAPSA in psoriatic arthritis.
2019 Metab Brain Dis Roflumilast ameliorates cognitive impairment in APPPS1 mice via cAMPCREBBDNF signaling and anti-neuroinflammatory effects.
2018 Dec Physiol Res Reduction of lung inflammation, oxidative stress and apoptosis by the PDE4 inhibitor roflumilast in experimental model of acute lung injury.
2018 Drug Des Devel Ther Pharmacokinetics of single- and multiple-dose roflumilast: an open-label, three-way crossover study in healthy Chinese volunteers.
2018 Dec Psychopharmacology (Berl) An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients.
2019 Jan Biochem Biophys Res Commun Phosphodiesterase 4B is an effective therapeutic target in colorectal cancer.
2019 J Am Acad Dermatol Apremilast for moderate hidradenitis purativa: Results of a randomized controlled trial.
2018 J Manag Care Spec Pharm Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis.
2019 Arthritis Rheumatol Ibudilast Inhibits Chemokine Expression in Rheumatoid Arthritis Synovial Fibroblasts and Exhibits Immunomodulatory Activity in Experimental Arthritis.
2019 Int Urol Nephrol The phosphodiesterase type 4 inhibitor roflumilast presses inflammation to improve diabetic bladder dysfunction rats.
2018 Arerugi